Madrigal Pharmaceuticals, Inc. MDGL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$94.39M-28.9% | -$58.58M+1.4% | -$114.19M-6.8% | -$42.28M+72.2% | -$73.24M+50.4% | ||
| $386K+1.8% | $392K+8.0% | $358K+20.1% | $377K+41.2% | $379K+126% | ||
| $34.02M+62.5% | $25.79M+45.9% | $26.25M+46.7% | $25.16M+3.1% | $20.93M+5.2% | ||
| $449K+3.0% | $468K-2.9% | $329K-31.5% | $371K-21.4% | $436K-33.4% | ||
| $52.88M+595% | $21.19M-9.3% | $34.05M+44.5% | $17.8M+158% | $7.61M— | ||
| $22.19M+4.8% | $1.73M-93.2% | $5.82M+254% | $8.26M+32.8% | $21.17M+2,379% | ||
| $3.58M+332% | $4.94M— | $5.96M-83.9% | -$4.08M+45.8% | -$1.54M+86.6% | ||
| $4.29M+909% | —— | $187.54M+1,118% | $33.31M+42.7% | -$530K-123% | ||
| $40.65M+330% | —— | —— | $35.36M+3,711% | $9.46M-13.1% | ||
| $2.44M— | —— | —— | -$942K— | $0— | ||
| -$167.44M-88.4% | -$133.46M-27.7% | —— | -$47.05M+65.1% | -$88.89M+40.4% | ||
| $3.85M— | —— | $857K+10.0% | $0-100% | $0-100% | ||
| $157.83M+20.7% | $212.96M-39.2% | $478.21M+14.9% | $225.53M-19.7% | $130.81M+55.4% | ||
| $353.87M+20.1% | $240.15M-20.6% | $275.07M+28.3% | $273.39M+66.9% | $294.69M+61.4% | ||
| $192.19M+17.3% | $27.58M+158% | —— | $47.86M+139% | $163.88M+67.1% | ||
| $2.33M-73.0% | —— | —— | —— | $8.64M— | ||
| $2.33M-73.0% | $8.96M-54.7% | $236.65M+3,071% | $1.74M-98.7% | $8.64M-98.5% | ||
| $1.32M— | —— | —— | —— | $0— | ||
| $28.41M-66.0% | —— | $109.5M— | $2.55M— | $83.63M-84.0% | ||
| $449K+3.0% | $468K-2.9% | $329K-31.5% | $371K-21.4% | $436K-33.4% | ||
| $3.58M+332% | $4.94M— | $5.96M-83.9% | -$4.08M+45.8% | -$1.54M+86.6% | ||
| $1.98M-30.6% | $2.4M+118% | $202K— | $513K+105% | $2.85M+307% | ||
| $40.65M+330% | —— | —— | $35.36M+3,711% | $9.46M-13.1% | ||
| $408K+629% | $1.55M— | $1.55M+439% | $55K— | $56K— | ||
| $2.44M— | —— | —— | -$942K— | $0— | ||
| $353.87M+20.1% | $240.15M-20.6% | $275.07M+28.3% | $273.39M+66.9% | $294.69M+61.4% | ||
| $2.98M— | —— | —— | —— | $0— | ||
| $1.67M— | —— | —— | $4M+233% | $0— | ||
| -$171.28M-92.7% | -$133.07M-27.1% | —— | -$47.05M+65.2% | -$88.89M+40.5% | ||
| -$171.28M-92.7% | -$133.07M-27.1% | —— | -$47.05M+65.2% | -$88.89M+40.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Madrigal Pharmaceuticals, Inc. generate?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
- What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
- After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
- Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
